- What approach to ALK-positive NSCLC?2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- When not even four ALK inhibitors are enough2020 | Faculty of Medicine in Pilsen
- New treatment options for ALK-positive patients with NSCLC krizotinibem2016 | Publication without faculty affiliation
- Treatment of ALK positive non-small cell lung cancer2021 | First Faculty of Medicine
- Alecensa - a new hope for patients with ALK positive non-small cell lung cancer2018 | Second Faculty of Medicine
- Case reports of patients with ALK-positive NSCLC and brain metastases2023 | First Faculty of Medicine
- Crizotinib - Still "gold standard" for patients with pulmonary adenocarcinoma with ALK translocation?2017 | Faculty of Medicine in Pilsen
- The present and future of ALK - testing in non-small cell lung carcinoma2017 | Faculty of Medicine in Hradec Králové
- Case report of a patient with metastatic non-small cell lung cancer with positive ALK gene rearrangement treated in the first line with alectini2020 | Publication without faculty affiliation
- Patient with NSCLC and brain metastases and positive reassortment ALK treated with alectinib - case report2020 | Publication without faculty affiliation
- Ceritinib - a new hope for patients with ALK-positive translocation of non-small-cell lung cancers +12015 | Faculty of Medicine in Pilsen
- Do metastases in the brain in a tumor with ALK translocation always mean ineffectiveness of crizotinib therapy?2017 | Faculty of Medicine in Pilsen
- Non-small cell lung cancer with ALK and R0S1 genes rearregement2018 | Faculty of Medicine in Pilsen
- Long time successful treatment of a young patient suffering from advanced ALK rearreged lung adenocarcinoma2018 | Faculty of Medicine in Pilsen, Second Faculty of Medicine
- Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic2018 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Optimal procedure in treatments of advanced ALK-positive and ROS1-positive non-small cell lung cancers2019 | Third Faculty of Medicine
- Identification of an optimal algorithm for effective diagnostics of non-small cell lung cancer with ALK gene rearrangement - implementation of the method and practical experiences with routine diagnostics2017 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Rare case of choroidal metastasis in ALK-positive NSCLC that responds to crizotinib2019 | First Faculty of Medicine
- Lorlatinib in a pretreated patient with ALK-positive lung adenocarcinoma2021 | Third Faculty of Medicine
- First experience on crizotinib therapy in non small cell lung cancer patient with EML-4 ALK translocation in Czech republic2012 | Faculty of Medicine in Pilsen
- First experiences with detecting ALK (anaplastic lymphoma kinase) gene rearrangement and administration of crizotinib in selected patients with non-small cell lung cancer (NSCLC)2012 | Faculty of Medicine in Pilsen
- Lorlatinib in the treatment of non-small cell lung cancer2020 | First Faculty of Medicine
- Současné možnosti léčby ALK-pozitivního NSCLC2021 | First Faculty of Medicine
- Dlouhodobé přežívání pacientky s ALK pozitivním metastatickým adenokarcinomem plic2019 | First Faculty of Medicine
- ALK-driven non-small cell lung cancer: Prevention, prophylaxis, and treatment of brain metastases2021 | Faculty of Medicine in Pilsen
- Anaplastic Large Cell Lymphoma: a Review2000 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Targeted treatment of bronchogenic carcinoma2020 | First Faculty of Medicine
- Atezolizumab in the treatment of non-small cell lung cancer patients with EGFR and ALK mutation or rearrangement2019 | First Faculty of Medicine
- Molecular Screening in ALK-Positive Anaplastic Large Cell Lymphoma: ALK Analysis, NGS Fusion Gene Detection, and T-cell Receptor Immunoprofiling2024 | Second Faculty of Medicine, Third Faculty of Medicine